Last reviewed: June 7, 2026 Last updated: June 7, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Transitioning from invasive surgeries to eye-drop therapy through targeted protein stabilization is a brilliant medical approach
NHS access requires meeting NICE criteria: for diabetes when other treatments fail, or for weight management with BMI 35 kg/m plus comorbidities after lifestyle intervention
If serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging, the patient should be further evaluated
No universal dose: appropriate use depends on an individuals health profile and is determined by a licensed provider, not a standard number from the internet
Additionally, with equivocal findings in DR and NAION, discussing personalized ocular risk of starting GLP-1RA in patients is key, and considering increased follow-up frequency after medication initiation may be warranted